| Autor: |
Dalal PJ; Department of Medicine, Northwestern Feinberg School of Medicine, Chicago, IL, USA., Patel NP; Department of Medicine, Northwestern Feinberg School of Medicine, Chicago, IL, USA., Feinstein MJ; Department of Medicine, Division of Cardiology, Northwestern Feinberg School of Medicine, Chicago, IL, USA., Akhter N; Department of Medicine, Division of Cardiology, Northwestern Feinberg School of Medicine, Chicago, IL, USA. |
| Abstrakt: |
This review summarizes the current literature on the adverse cardiac effects of CAR T-cell therapy. Case reports and series suggest that major adverse cardiovascular events are not uncommon after CAR T-cell therapy; however, limited data exist regarding incidence, pathophysiology, and prevention strategies related to CAR T-associated cardiovascular events. As cellular therapy advances and the indications for its use continue to expand, it is essential to better understand its associated cardiovascular toxicities. Biomarkers, cardiac imaging, longitudinal data from larger populations, and translational research are all essential areas for further research. Interestingly, CAR T-cell therapy can also be used to reverse cardiac fibrosis in murine models. Altogether this underscores the need to broadly understand how T-cells, endogenous and engineered, may impact cardiovascular diseases. |
